Investor Alert

July 8, 2020, 2:24 a.m. EDT

AstraZeneca gets EU OK for pancreatic cancer drug

Watchlist Relevance

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Sabela Ojea

AstraZeneca PLC said Wednesday that its Lynparza medicine has been approved in the European Union for patients diagnosed with germline BRCA-mutated metastatic pancreatic cancer, one of the most common cancers with the lowest survival rate.

The pharmaceutical giant said the approval was based on results from the Phase 3 Polo trial.

Only around 5% to 7% of these patients with metastatic pancreatic cancer have a germline BRCA mutation, the London-listed company said.

"Lynparza is approved in the U.S. and several other countries as a 1st-line maintenance treatment for patients with gBRCAm metastatic pancreatic cancer based on the Phase 3 Polo trial , with ongoing regulatory reviews in other regions," AstraZeneca said.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

This Story has 0 Comments
Be the first to comment
More News In

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.